Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: Phase II open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy

 


Phase II open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy


Trial Focus

Prostate Cancer

Objective

         This is a clinical trial of investigational drug GTx-758 which will be administered orally.

IRB Protocol #

12-1660

Trial Status

OPEN

Principle Investigator

THOMAS FLAIG

Sponsor

GTx Inc

Contact

MICHAEL WACKER at (720)848-3427 or MICHAEL.WACKER@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. You will take the study treatment daily for about 3 months. If you do not show signs of PSA or disease progression you will continue taking the study treatment daily for up to a year. Follow up visits include an end of study clinic visit 7 days after participation in the study is discontinued and one more 30 days later. // Eligibility criteria include but are not limited to 18 years or older with metastatic castration resistant prostate cancer.Eligibility criteria include but are not limited to 18 years or older with metastatic castration resistant prostate cancer.